Agenus Announces Appointment of Tom Harrison to Board of Directors

Agenus Inc. (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced the appointment of Tom Harrison to its Board of Directors. Mr. Harrison brings a wealth of experience and a proven track record in healthcare advertising, branding, and strategic advising.

Tom Harrison's Background Highlights:

• Chairman Emeritus of Diversified Agency Services (DAS), Omnicom Group Inc.: Harrison led the world's largest group of marketing services companies, overseeing an unparalleled range of services including public relations, crisis management, branding, and healthcare advertising. Under his leadership, DAS grew to become the largest division within Omnicom Group, generating annual revenues of over $6 billion.
• Experience in Leading Marketing Services Companies: Harrison's tenure at DAS saw the division expand to over 5,000 worldwide clients, accounting for more than 50% of Omnicom's total revenues. He acquired and led a group of companies that became influential in their respective disciplines.
• Proven Track Record in Healthcare Advertising: Before joining Omnicom, Harrison co-founded Harrison & Star Business Group, which became the most successful and rapidly growing agency in the healthcare industry. His unique approach fused high science with high creativity, positioning the agency as a leader in the market.
• Senior Operating Partner at Merida Capital Partners: In his current role, Harrison focuses on strategic and operational advising across Merida's portfolio companies, contributing his expertise to the dynamic cannabis industry.

In addition to his role at Merida Capital Partners, Mr. Harrison serves on the boards of AFC Gamma and Acurx Pharmaceuticals.

“We are thrilled to welcome Tom Harrison to our Board of Directors,” said Garo Armen, PhD, Chairman and CEO of Agenus. “Tom’s extensive experience in healthcare advertising and strategic advising, combined with his proven leadership skills, will be invaluable as we continue to advance our mission of harnessing the power of the immune system to bring innovative therapies to patients.”

Educating the World About Agenus and Our Pipeline

As Agenus continues to develop its robust pipeline of novel immunotherapy candidates, the importance of effectively communicating our scientific advancements and therapeutic potential to a global audience cannot be overstated. Tom Harrison’s background in leading large-scale marketing and communications efforts uniquely positions him to drive these initiatives forward.